CliffBio
small molecule

VIDAZA

AZACITIDINE

Loss of exclusivityMay 2029FDA regulatory exclusivity expiry
CompanyBristol-Myers Squibb →See this company's full patent-cliff portfolio

Drug detail

Brand nameVIDAZA
Active ingredientAZACITIDINE
Strength100MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalMay 2004
Marketing statusRX

Regulatory exclusivity

CodeExpires
ODE-399May 2029

More from Bristol-Myers Squibb

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

VIDAZA patent cliff — loss of exclusivity May 2029 | CliffBio